Metabolic dysfunction associated liver disease (MASLD) is the most common liver disease worldwide, and a leading cause of liver-related morbidity and mortality. Current prevalence is approximately 30% of the global population with an incidence of 4.6 per 100 patient years[1]. Although controversial, MASLD may be an independent predictor of cardiovascular disease. The globalization of MASLD runs parallel to the continuously rising prevalence of obesity, associated metabolic syndrome and insulin resistance, which all promote hepatic triglyceride accumulation.
